您的位置: 首页 > 2015年5月 第46卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

不同起源神经母细胞瘤N-myc基因扩增情况研究

A Study of the status of N-myc amplification in neuroblastoma originating from different sites

来源期刊: 广州医药 | 16-18 发布时间:2021-11-30 收稿时间:2025/11/13 16:46:35 阅读量:13
作者:
关键词:
神经母细胞瘤N-myc基因扩增腹膜后
NeuroblastomaN-myc amplificationRetroperitoneal
DOI:
10.3969/j.issn.1000-8535.2015.03.004
收稿时间:
2014-11-17 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 了解不同类型神经母细胞瘤的生物学特性。方法 在本研究中,对新诊断神经母细胞瘤患者的生物学特点(N-myc基因扩增)与临床特点进行了比较。结果 共49例神经母细胞瘤,起源于腹膜后35例,其他14例。两个组呈现出不同的N-myc基因扩增情况(P<0.05)。结论 不同临床类型的神经母细胞瘤存在有不同的生物学特性发布情况。
Objective To investigate the biological characteristics of neuroblastomas originating from different sites. Methods Fluorescent in situ hybridization (FISH) was employed to detect the status of N-myc amplification in patients with newly diagnosed neuroblastoma originating from different sites from July 2011 to June 2013. Results A total of 49 cases of patients with newly diagnosed neuroblastoma were identified in the study, 35 cases of neuroblastoma originating from retroperitoneal site, 14 cases from other primary sites. There were significant differences in the N-myc amplification between the two groups(P<0.05). Conclusion Patients with neuroblastomas originating from extra-retroperitoneal sites might show a more favorable biological characteristics than from retroperitoneal site.
1、 Berdon WE, Stylianos S, Ruzal-Shapiro C, et al.M. Neuroblastoma arising from the organ of Zuckerkandl: an unusual site with a favorable biologic outcome[J].Pediatr Radiol,1999,29(7):497-502. Berdon WE, Stylianos S, Ruzal-Shapiro C, et al.M. Neuroblastoma arising from the organ of Zuckerkandl: an unusual site with a favorable biologic outcome[J].Pediatr Radiol,1999,29(7):497-502.
2、 Moukheiber AK, Nicollas R, Roman S, et al. Triglia JM. Primary pediatric neuroblastic tumors of the neck[J].Int J Pediatr Otorhinolaryngol,2001,60(2):155-161. Moukheiber AK, Nicollas R, Roman S, et al. Triglia JM. Primary pediatric neuroblastic tumors of the neck[J].Int J Pediatr Otorhinolaryngol,2001,60(2):155-161.
3、 Cruccetti A, Kiely EM, Spitz L, et al. Pelvic neuroblastoma: low mortality and high morbidity[J]. J Pediatr Surg,2000,35(5):724-728. Cruccetti A, Kiely EM, Spitz L, et al. Pelvic neuroblastoma: low mortality and high morbidity[J]. J Pediatr Surg,2000,35(5):724-728.
4、 Horiuchi A, Muraji T, Tsugawa C, et al. Thoracic neuroblastoma: outcome of incomplete resection[J]. Pediatr Surg Int,2004,20(9):714-718. Horiuchi A, Muraji T, Tsugawa C, et al. Thoracic neuroblastoma: outcome of incomplete resection[J]. Pediatr Surg Int,2004,20(9):714-718.
5、 Calafiore L, Amoroso L, Della Casa Alberighi O, et al. Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma[J]. Ann Oncol, 2013,24(5): 1406-1413. Calafiore L, Amoroso L, Della Casa Alberighi O, et al. Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma[J]. Ann Oncol, 2013,24(5): 1406-1413.
6、 Suita S, Tajiri T, Sera Y, et al. The characteristics of mediastinal neuroblastoma[J]. Eur J Pediatr Surg,2000,10(6):353-359. Suita S, Tajiri T, Sera Y, et al. The characteristics of mediastinal neuroblastoma[J]. Eur J Pediatr Surg,2000,10(6):353-359.
7、 Zhang Z, Yu H, Huang J, et al. The TRPM6 kinase domain determines the Mg·ATP sensitivity of TRPM7/M6 heteromeric ion channels[J]. J Biol Chem,2014,289(8):5217-5227. Zhang Z, Yu H, Huang J, et al. The TRPM6 kinase domain determines the Mg·ATP sensitivity of TRPM7/M6 heteromeric ion channels[J]. J Biol Chem,2014,289(8):5217-5227.
8、 Hossain MM, Banik NL, Ray SK.N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification[J]. Gene,2013,529(1):27-36. Hossain MM, Banik NL, Ray SK.N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification[J]. Gene,2013,529(1):27-36.
9、 Pession A, Tonelli R. The mycn oncogene as a specific and selective drug target for peripheral and central nervous system tumors[J]. Curr Cancer Drug Targets,2005,5(4):273-283. Pession A, Tonelli R. The mycn oncogene as a specific and selective drug target for peripheral and central nervous system tumors[J]. Curr Cancer Drug Targets,2005,5(4):273-283.
10、 Joshi VV,Cantor AB,Brodeur GM,et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group[J]. Cancer 1993,71(10):3173-3181. Joshi VV,Cantor AB,Brodeur GM,et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group[J]. Cancer 1993,71(10):3173-3181.
11、 Shimada H,Ambros IM,Dehner LP,et al. The International Neuroblastoma Pathology Classification (the Shimada system) [J]. Cancer,1999,86(2):364-372. Shimada H,Ambros IM,Dehner LP,et al. The International Neuroblastoma Pathology Classification (the Shimada system) [J]. Cancer,1999,86(2):364-372.
12、 Liu YL, Miser JS, Hsu WM. Risk-directed therapy and research in neuroblastoma[J]. J Formos Med Assoc, 2014,113(12): 887-889. Liu YL, Miser JS, Hsu WM. Risk-directed therapy and research in neuroblastoma[J]. J Formos Med Assoc, 2014,113(12): 887-889.
13、 郑兆俭.神经母细胞瘤6例报告[J]. 哈尔滨医药,1990(1):27-29. 郑兆俭.神经母细胞瘤6例报告[J]. 哈尔滨医药,1990(1):27-29.
14、 Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma[J]. Lancet,2007,369 (9579): 2106-2120. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma[J]. Lancet,2007,369 (9579): 2106-2120.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录